<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00463697</url>
  </required_header>
  <id_info>
    <org_study_id>B2C106996</org_study_id>
    <nct_id>NCT00463697</nct_id>
  </id_info>
  <brief_title>A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients</brief_title>
  <official_title>A Randomized, Single-dose, Dose-ascending, Double Blind, Placebo-controlled, 5-way Crossover Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Doses of GW642444M With Magnesium Stearate in Asthmatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will involve the use of a new compound, GW642444 that is being developed for the
      treatment of asthma and chronic obstructive pulmonary disease (COPD). It works by acting on
      cells in the lungs, causing some of the muscles around the lungs to relax and open up better
      (bronchodilation), making breathing easier. When a medicine is made into a form ready to be
      given to patients, the active ingredient is often prepared with another ingredient called a
      salt to help make it stable, and inactive ingredients are often added. Inactive ingredients
      might be used to help a medicine work better, to make it easier to produce the medicine, or
      to make it easier to get an accurate dose of medicine. In previous studies the study drug has
      been given as a dry powder containing either the &quot;H&quot; salt (with the inactive ingredient
      lactose), or containing the &quot;M&quot; salt (with the inactive ingredients lactose and cellobiose
      octaacetate). The &quot;M&quot; salt form of the study drug has been altered to contain lactose and a
      new inactive ingredient called magnesium stearate (instead of cellobiose octaacetate).

      Participants in this study will receive both the &quot;H&quot; salt (GW642444H) and the new &quot;M&quot; salt
      (GW642444M) containing magnesium stearate. This study will be the first time the new &quot;M&quot; salt
      form of the study drug will be given to asthmatic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2007</start_date>
  <completion_date type="Actual">August 4, 2007</completion_date>
  <primary_completion_date type="Actual">August 4, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>General safety and tolerability of the new formulation of GW642444 as measured by ECG, blood pressure, pulse rate and blood and urine tests. Serial measurements are made over 24 hours on 5 separate occasions (separated by 1 - 2 weeks).</measure>
    <time_frame>Serial measurements are made over 24 hours on 5 separate occasions (separated by 1 - 2 weeks).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Airways relaxation assessed by lung function tests. Effect of study medicine on the body and amount of medicine in the body measured by potassium, glucose and medicine in blood samples. Measurements made over 24 hours on 5 occasions (1-2 weeks apart).</measure>
    <time_frame>Measurements made over 24 hours on 5 occasions (1-2 weeks apart).</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>GW642444M 25mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will inhale single dose of GW642444M 25 mcg via a DISKUS device in morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GW642444M 100mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will inhale single dose of GW642444M 100 mcg via a DISKUS device in morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GW642444M 400mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will inhale single dose of GW642444M 400 mcg via a DISKUS device in morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GW642444H 100mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will inhale single dose of GW642444H 100 mcg via a DISKUS device in morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will inhale single dose of Placebo via a DISKUS device in morning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW642444H (100mcg)</intervention_name>
    <description>H salt</description>
    <arm_group_label>GW642444H 100mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW642444M (25, 100 &amp; 400 mcg)</intervention_name>
    <description>M salt</description>
    <arm_group_label>GW642444M 25mcg</arm_group_label>
    <arm_group_label>GW642444M 400mcg</arm_group_label>
    <arm_group_label>GW642444M 100mcg</arm_group_label>
    <other_name>placebo</other_name>
    <other_name>GW642444M (25</other_name>
    <other_name>100 &amp; 400 mcg)</other_name>
    <other_name>GW642444H (100mcg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  male or female (of non-childbearing potential) between 18 - 70 years

          -  History of stable mild to moderate asthma

          -  non - smokers

          -  currently taking daily doses of inhaled fluticasone propionate 200 - 500 mcg (or
             equivalent)

          -  body weight &gt;50 kg with BMI 19-29.9 kg/m2

          -  normal ECG assessment

        Exclusion criteria:

          -  history of significant disease

          -  history of life threatening asthma

          -  recent respiratory tract infection

          -  recent change of asthma medication

          -  treatment with high dose inhaled corticosteroids or oral corticosteroids

          -  recent participation in another trial

          -  history of drug or alcohol abuse

          -  known allergies (excluding asthma)

          -  recent blood donation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/B2C106996?search=study&amp;search_terms=B2C106996#rs</url>
    <description>Results for study B2C106996 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013 Apr;26(2):256-64. doi: 10.1016/j.pupt.2012.12.001. Epub 2012 Dec 8.</citation>
    <PMID>23232038</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2007</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GW642444,</keyword>
  <keyword>magnesium stearate,</keyword>
  <keyword>asthmatic patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>B2C106996</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C106996</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C106996</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C106996</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C106996</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C106996</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C106996</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

